Developmental neuroscience

Baby Food Attorney Taking Cases for Parents of Kids with Autism and ADHD

Retrieved on: 
Wednesday, February 10, 2021
Psychiatric diagnosis, Branches of biology, Psychiatry, Abnormal psychology, Learning disabilities, Developmental neuroscience, Neurological disorders, Childhood psychiatric disorders, Autism, Attention deficit hyperactivity disorder, Metal toxicity

LOS ANGELES, Feb. 10, 2021 /PRNewswire/ -- The law firm of Baum Hedlund Aristei & Goldman is accepting toxic baby food lawsuit cases on behalf of parents of children with autism and ADHD who purchased foods from several leading brands.

Key Points: 
  • LOS ANGELES, Feb. 10, 2021 /PRNewswire/ -- The law firm of Baum Hedlund Aristei & Goldman is accepting toxic baby food lawsuit cases on behalf of parents of children with autism and ADHD who purchased foods from several leading brands.
  • These toxic metals are associated with autism, autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children.
  • The report also found that the companies knew their baby food products were tainted with high levels of toxic metals but decided to sell them anyway.
  • "The level of exposure to arsenic, lead, cadmium, and mercury known to be safe for infants is zero," attorney Pedram Esfandiary .

Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD

Retrieved on: 
Thursday, February 4, 2021
Developmental neuroscience, Neurosphere

"I'm thrilled to initiate this collaboration with Diamond, which promises to pave the way towards the translation of our discoveries into innovative clinical strategies."

Key Points: 
  • "I'm thrilled to initiate this collaboration with Diamond, which promises to pave the way towards the translation of our discoveries into innovative clinical strategies."
  • Diamond will also be working on a series of research studies in collaboration with Dr. Gobbi's laboratory.
  • "Working with commercial partners such as Diamond Therapeutics is an important step in realizing the benefits of research for society," said Mark Weber, Director of the Office of Innovation and Partnerships at McGill.
  • NeuroSphere is the McGill accelerator dedicated to innovation and partnership in neuroscience research funded through Healthy Brains, Healthy Lives (HBHL).

Coming Soon to Geneva: A Therapy Center Designed for Children with Autism

Retrieved on: 
Wednesday, January 27, 2021
Psychiatric diagnosis, Branches of biology, Psychiatry, Autism, Abnormal psychology, Learning disabilities, Autism spectrum, Developmental neuroscience, Developmental psychology, Geraldine Dawson, Autism rights movement

GENEVA, Ill., Jan. 27, 2021 /PRNewswire/ -- Caravel Autism Health has announced plans to open a new center in Geneva, Ill. designed to meet the unique needs of children with autism.

Key Points: 
  • GENEVA, Ill., Jan. 27, 2021 /PRNewswire/ -- Caravel Autism Health has announced plans to open a new center in Geneva, Ill. designed to meet the unique needs of children with autism.
  • Caravel Autism Health specializes in the evaluation, diagnosis, and treatment of children who are on the autism spectrum.
  • "Our goal is ensuring that children with autism have access to the best possible care and treatment outcomes," said Caravel Autism Health CEO Mike Miller.
  • An official grand opening for the new autism therapy center at 2323 Fargo Boulevard in Geneva is planned for March.

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Retrieved on: 
Wednesday, January 13, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Neurological disorders, Developmental neuroscience, Economy of New York City, NASDAQ, Autism

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Key Points: 
  • SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market.
  • The letter noted that as for the last 10 consecutive business days, from December 29, 2020 to January 12, 2021, the closing bid price of the Company's common stock has been at $1.00 per share or greater, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.
  • Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business.
  • Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns.

Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Developmental neuroscience, Biology, Proteins, Autoimmunity, Immunology, MuSK protein, Myasthenia gravis, Myasthenia

PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m.

Key Points: 
  • PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m.
  • A live webcast of the presentation will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • Following the presentation, a replay of the webcast will be available on the website for 90 days.
  • The Companys lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Retrieved on: 
Thursday, December 17, 2020
Branches of biology, Biology, Medical specialties, Immunology, Developmental neuroscience, Insulin-like growth factor 1, Antibody, Monoclonal antibody

This clinically validated technology provides for improved antibody half-life, which miRagen intends to leverage in its product candidate VRDN-002 to reduce dose and/or dosing frequency.

Key Points: 
  • This clinically validated technology provides for improved antibody half-life, which miRagen intends to leverage in its product candidate VRDN-002 to reduce dose and/or dosing frequency.
  • We are excited to leverage the Xtend technology in our next-generation IGF1R antibody program VRDN-002.
  • miRagen is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED).
  • miRagens most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED).

Autism Specialists Expanding Wisconsin Presence

Retrieved on: 
Wednesday, December 2, 2020
Autism, Abnormal psychology, Branches of biology, Psychiatric diagnosis, Psychiatry, Autism spectrum, Developmental neuroscience, Developmental psychology, Global perceptions of autism, Autism Speaks

These new centers will be led by clinical professionals who specialize in the evaluation, diagnosis, and treatment of autism spectrum disorder.

Key Points: 
  • These new centers will be led by clinical professionals who specialize in the evaluation, diagnosis, and treatment of autism spectrum disorder.
  • Caravel Autism Health was founded in Wisconsin by clinicians who specialize in working with children who have autism.
  • Founded in 2009, Caravel Autism Health is devoted to helping families navigate the challenges of childhood autism.
  • Caravel's team of autism health experts specializes in the evaluation, diagnosis, and treatment of children on the autism spectrum.

Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci Capital

Retrieved on: 
Monday, November 16, 2020
Mental health, Health, Other Health, Clinical trials, Research, Science, Biotechnology, Branches of biology, Neuroscience, Biology, Developmental neuroscience, Neurodevelopmental disorder, Parkinson's disease

Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET.

Key Points: 
  • Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET.
  • Axial Therapeutics is a clinical-stage, biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of the central nervous system and other gut-derived diseases.
  • The Company has built a pipeline of novel small molecules with lead programs to address the significant unmet patient needs associated with Parkinsons Disease and Autism Spectrum Disorder.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005171/en/

BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations

Retrieved on: 
Friday, November 13, 2020
Tyrosine kinase receptors, Branches of biology, PTPN11, Receptor tyrosine kinase, Tyrosine kinase, Cell biology, Biology, Growth factors, Developmental neuroscience, Proteins

BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Centers Therapeutics Discovery division .

Key Points: 
  • BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Centers Therapeutics Discovery division .
  • Part 1 is a dose escalation to establish the recommended Phase 2 dose (RP2D) of BBP-398.
  • Part 2 will examine preliminary anti-tumor activity in four cohorts of patients with certain molecular alterations.
  • As SHP2 regulates receptor tyrosine kinase signaling pathways commonly overly activated in cancer, targeting SHP2 may offer a potential new approach to treat this disease.

Melmark And Bancroft Construction Break Ground On New School Facility

Retrieved on: 
Wednesday, November 11, 2020
Psychiatric diagnosis, Branches of biology, Psychiatry, Abnormal psychology, Learning disabilities, Autism spectrum, Developmental neuroscience, Developmental psychology, Autism, Bancroft, Wilmington, Delaware

BERWYN, Pa., Nov. 11, 2020 /PRNewswire/ -- Melmark has partnered with Bancroft Construction to construct a new school facility at its service division in Berwyn, Pennsylvania.

Key Points: 
  • BERWYN, Pa., Nov. 11, 2020 /PRNewswire/ -- Melmark has partnered with Bancroft Construction to construct a new school facility at its service division in Berwyn, Pennsylvania.
  • Students who attend the Melmark School have a diagnosis of autism spectrum disorders and other intellectual and developmental disabilities, which may be secondary to complex behavioral profiles.
  • The school is being constructed through philanthropic support, with donations from families, corporate partners, foundations, event proceeds, and other major donors.
  • Bancroft Construction Company is a full-service Construction Management, General Contracting, Design-Build, Preconstruction, Virtual Design, and Program Management firm serving the Mid-Atlantic region with offices in Wilmington, DE, Princeton, NJ, and Salisbury, MD.